InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.57
(
-0.15%
)
Bitcoin
65,112.02
(
0.22%
)
Post# of 252255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119875
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Friday, 03/18/2022 12:34:39 PM

Friday, March 18, 2022 12:34:39 PM

Post# of 252255
Apexigen goes public via SPAC-merger with BCAC:

https://www.globenewswire.com/news-release/2022/03/18/2405858/0/en/Apexigen-and-Brookline-Capital-Acquisition-Corp-Announce-Business-Combination-Agreement-to-Create-Publicly-Listed-Immuno-oncology-Company.html

Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. [Rhetorical: What else would an I-O agent do?]

The deal is expected to close in Jul 2022, and the ticker symbol will become ‘APGN’. The nominal deal value is $205M.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up